| Identification | Back Directory | [Name]
L-Ornithinamide, N-[6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-L-valyl-N5-(aminocarbonyl)-N-[4-[[[[(2-aminoethyl)amino]carbonyl]oxy]methyl]phenyl]-, 2,2,2-trifluoroacetate (1:1) | [CAS]
1616727-21-9 | [Synonyms]
MC-VC-PAB-NH2 (TFA)
L-Ornithinamide, N-[6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-L-valyl-N5-(aminocarbonyl)-N-[4-[[[[(2-aminoethyl)amino]carbonyl]oxy]methyl]phenyl]-, 2,2,2-trifluoroacetate (1:1) | [Molecular Formula]
C33H47F3N8O10 | [MOL File]
1616727-21-9.mol | [Molecular Weight]
772.78 |
| Hazard Information | Back Directory | [Uses]
MC-VC-PAB-NH2 TFA is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs)[1]. | [References]
[1] Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337. DOI:10.1038/nrd.2016.268 |
|
|